VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

ASH 2014 | Phase III trial shows vosaroxin improves overall survival in acute myeloid leukaemia

At a press conference during the 2014 American Society of Hematology (ASH) Annual Meeting, Prof Farhad Ravandi (The University of Texas MD Anderson Cancer Center, Houston, TX) discusses the phase III double-blind randomized controlled multinational VALOR study, which evaluated vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first-relapsed or refractory acute myeloid leukaemia.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter